Ebris Pharma

Ebris Pharma is a Swiss-based pharmaceutical company headquartered in Lugano, specializing in the development and commercialization of innovative therapies for oncology, rare diseases, and supportive care. Founded in 2018 by experienced leaders from the Helsinn Group, the company operates as a boutique pharmaceutical firm focusing on high-potential, late-stage assets. Ebris Pharma utilizes a lean business model to identify and advance clinical programs through strategic licensing and international partnerships. The company leverages the deep industry expertise of its management team to address significant unmet medical needs in niche therapeutic areas. Its operations are centered on bridging the gap between early-stage research and global market availability.